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We tested serum samples from pigs infected or vac-
cinated with European swine inﬂ  uenza viruses (SIVs) in he-
magglutination-inhibition assays against pandemic (H1N1) 
2009 virus and related North American SIVs. We found 
more serologic cross-reaction than expected. Data sug-
gest pigs in Europe may have partial immunity to pandemic 
(H1N1) 2009 virus. 
P
andemic (H1N1) 2009 virus is a reassortant of >2 circu-
lating swine inﬂ  uenza viruses (SIVs) (1). Six gene seg-
ments, including the gene encoding a classical H1 hemag-
glutinin (HA), are similar to ones found in triple reassortant 
SIVs circulating in pigs in North America. The neuramini-
dase (NA) and matrix genes originate from Eurasian avian-
like H1N1 SIV. This speciﬁ  c reassortant had never been 
found in swine when it was ﬁ  rst detected in humans. How-
ever, during May–October 2009, pandemic (H1N1) 2009 
virus was isolated from swine in Canada, Argentina, Aus-
tralia, Singapore, (Northern) Ireland, Norway, the United 
States, Japan, and Iceland (2). Humans were suspected to 
be the source of infection; pigs did not contribute to spread 
of the virus in humans.
Recent experimental studies conﬁ  rmed  pandemic 
(H1N1) 2009 virus can become established in swine popu-
lations (3,4). A key question is whether immunity to cir-
culating SIVs, which differ antigenically and genetically in 
different parts of the world, protects pigs against pandemic 
(H1N1) 2009 virus. Three SIV subtypes are cocirculating in 
European swine populations: an avian-like subtype H1N1 
virus introduced from wild birds in 1979, a human-like 
subtype H3N2 reassortant with HA and NA genes acquired 
from descendants of Hong Kong/68 pandemic virus, and a 
subtype H1N2 reassortant virus, which acquired H1 from 
human inﬂ  uenza (H1N1) viruses in the 1980s (5). We aimed 
to clarify whether pigs infected or vaccinated with these 
viruses have cross-reactive antibodies against pandemic 
(H1N1) 2009 virus or related North American SIVs, both of 
which have an antigenically distinct, classical H1 HA.
The Study
We tested 66 swine sera obtained from previous ex-
perimental studies (6). All pigs were negative for SIV anti-
bodies at the start of the experiments. Serum samples were 
collected 3–4 weeks after the last infection or immuniza-
tion. Immunization categories, experimental groups, and 
inﬂ  uenza virus strains used are shown in the Table.
Twenty-seven pigs were intranasally (IN) inocu-
lated with 7.0 log10 50% egg infectious doses of swine/
Belgium/1/98 (avian-like swine inﬂ  uenza [H1N1]), swine/
Gent/7625/99 (reassortant inﬂ  uenza [H1N2] with human-
lineage HA), swine/Flanders/1/98 (reassortant inﬂ  uenza 
[H3N2] with human-lineage HA), or some combination 
of the three. These viruses are representative of prevailing 
SIVs in western Europe. Two groups received a single in-
oculation with either SIV (H1N1) or SIV (H1N2). Three 
groups received dual, consecutive inoculations with 2 SIV 
subtypes at a 4-week interval.
Twenty-four pigs received 2 intramuscular (IM) doses 
of commercial, inactivated SIV vaccine, at a 4-week in-
terval. One vaccine contained a classical swine-lineage 
subtype H1N1 virus, A/New Jersey/8/76; the remaining 3 
contained various avian-like subtype H1N1 SIVs (Table). 
The vaccines contained various types of adjuvants.
Six pigs were ﬁ   rst inoculated IN with swine/
Belgium/1/98 (H1N1) followed by a single IM administra-
tion of New Jersey/8/76-based SIV vaccine 5 weeks later. 
Nine pigs were hyperimmunized against various European 
SIVs (Table) by IN inoculation, followed by an IM innocu-
lation with the same virus in combination with Freund’s 
complete adjuvant 4 weeks later. 
All serum samples were examined in hemagglu-
tination-inhibition (HI) assays against the European 
subtype H1N1, H1N2, and H3N2 viruses listed above; 
3 North American SIVs with a classical H1; and A/
California/04/2009, a prototype pandemic (H1N1) 2009 
virus (7). The North American SIVs included swine/
Iowa/H04YS2/2004 (triple reassortant inﬂ  uenza [H1N1]), 
swine/Ontario/11112/04 (reassortant inﬂ  uenza [H1N1]), 
and swine/Indiana/9K035/99 (triple reassortant inﬂ  uenza 
[H1N2]). Low amino acid homology was present in the 
HA1 region of the HA gene between the European H1 
SIVs used for infection of pigs and the North American 
H1 SIVs (range 70%–75%) or the pandemic (H1N1) 2009 
virus (69%–72%). When compared with avian-like in-
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ﬂ  uenza (H1N1) strains in European vaccines, the New 
Jersey/8/76 vaccine strain was more closely related to 
North American SIVs (77%–81% vs. 92%–94%) and pan-
demic (H1N1) 2009 virus (72%–75% vs. 90%).
HI antibodies induced by a single infection with Euro-
pean subtype H1N1 or H1N2 SIVs did not cross-react with 
North American H1 SIVs or with pandemic (H1N1) 2009 
virus. In contrast, consecutive infections with 2 European 
subtypes frequently induced cross-reactive antibodies, 
even though European viruses do not contain a classical 
swine H1 HA.
Three European vaccines also induced cross-reactive 
antibodies to North American H1 SIVs, and 2 induced an-
tibody titers >20 to pandemic (H1N1) 2009 virus in most 
pigs. HI titers against pandemic virus were lower with A/
New Jersey/8/76-based vaccine than with vaccine contain-
ing an avian-like SIV (H1N1).
A single vaccination with A/New Jersey/8/76-based 
vaccine induced only minimal HI antibody titers in inﬂ  uen-
za-naive pigs, but existing antibody titers (data not shown) 
to European avian-like subtype H1N1 SIV in pigs previ-
ously infected with this virus dramatically increased, even 
though these viruses contain HA proteins of the avian and 
classical swine lineages respectively. All pigs had antibod-
ies to the viruses with a classical swine H1 HA, including 
pandemic (H1N1) 2009 virus.
Finally, hyperimmunization with European SIVs of 
subtype H1N1, H3N2, or H1N2 resulted in high titers to 
the homologous viruses. Cross-reactions with viruses with 
a classical H1 were consistently observed with serum 
samples from pigs hyperimmune to avian-like European 
inﬂ  uenza (H1N1) viruses, but they were rare or absent after 
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Table. Serologic cross-reactivity between North American H1 SIVs and pandemic (H1N1) 2009 virus after experimental infection 
and/or immunization of pigs by various methods with European SIVs* 
Range of antibody titers of positive animals (no. pigs with HI antibody titers t10) 
European SIVs  North American H1 SIVs 
Group 
No.
pigs
Swine/ 
Belgium/
98 (H1N1) 
avH1†
Swine/ 
Gent/99
(H1N2) 
huH1†
Swine/ 
Flanders/98
(H3N2) 
huH3†
Swine/ 
Iowa/2004
(H1N1) 
cH1†
Swine/ 
Ontario/ 
2004 (H1N1) 
cH1†
Swine/ 
Indiana/99
(H1N2) 
cH1†
Pandemic
(H1N1) 
2009 cH1†
Infection‡
  H1N1 (avH1†)  6 40–160 (6)  –§ – – – – 10 (1) 
  H1N2 (huH1†)  6 – 40–160 (6)  – – – – –
  H1N1 (avH1†)- 4w -  
 H1N2  (huH1†) 
5 80–160 (5)  20–40 (5)  – 20 (4)  10–20 (5)  10–20 (5)  20–40 (5) 
  H1N2 (huH1†)- 4w -  
 H1N1  (avH1†) 
4 80–160 (4)  160–320 (4)  10 (3)  10–40 (4)  20–80 (4)  20–40 (4)  20–160 (4) 
  H1N1 (avH1†)- 4w -  
 H3N2  (huH3†) 
6 40–160 (6)  – 20–80 (6)  – 10–40 (3)  10–20 (4)  10–40 (6) 
Double vaccination¶
  New Jersey/8/76  
 (H1N1,  cH1†) 
6 10–40 (6)  10 (1)  10–80 (5)  80–160 (6) 20–80 (6)  80–320 (6) 10–20 (5) 
 Swine/Netherlands/25/   
  80 (H1N1, avH1†) 
6 10–40 (6)  10 (1)  10–160 (6)  20–40 (5)  10–80 (6)  10–40 (6)  10 (3) 
 Swine/Belgium/230/92 
 (H1N1,  avH1†) 
6 20–640 (6)  10–20 (2)  20–320 (6)  10–320 (5) 10–320 (6)  10–160 (5) 10–640 (5) 
 Swine/Haselunne/2617/ 
  2003 (H1N1, avH1†) 
6 10–40 (6)  40–160 (6)  20 (6)  – 20 (1)  10–20 (5)  10 (1) 
Infection# followed by single vaccination 
  H1N1 (avH1†)- 4w -  
 New  Jersey/8/76 
6 640–2,560
(6)
10 (3)  10 (1)  40–80 (6)  40–80 (6)  80–320 (6) 40–80 (6) 
Hyperimmunization** 
 H1N1  (avH1†)  3 320–1,280
(3)
10–20 (2)  – 40–160 (3) 40–160 (3)  40–80 (3)  40–160 (3) 
  H1N2 (huH1†)  3 40 (1)  320–1,280
(3)
– 20 (1)  10–80 (2)  40 (1)  80 (1) 
 H3N2  (huH3†)  3 – – 160–640
(3)
––– –
*SIV, swine influenza virus. 
†Phylogenetic lineage of the hemagglutinin gene: c, classical swine; hu, human; av, avian. 
‡Infection with swine/Belgium/1/98 (H1N1), swine/Gent/7625/99 (H1N2), or swine/Flanders/1/98 (H3N2). 
§Antibody titers <10 in all pigs. 
¶Only the influenza (H1N1) vaccine component is shown. The first 3 vaccines are bivalent (subtypes H1N1, H3N2); the fourth is trivalent (subtypes H1N1, 
H3N2, H1N2). 
#Infection with swine/Belgium/1/98 (H1N1). 
**Each individual pig was hyperimmunized with a different European SIV isolate: subtype H1N1 viruses were swine/Finistère/2899/82,
swine/Belgium/1/98, and swine/Gent/132/2005; subtype H1N2 viruses were swine/Scotland/410440/94, swine/Gent/7625/99, and swine/Gent/177/2002; 
bt H3N2 i i /G t/1/84 i /Fl d /1/98 d i /G t/131/2005hyperimmunization with subtype H1N2 or H3N2 strains. 
Conclusions
A large antigenic and genetic distance exists between 
European H1 SIVs and viruses with a classical H1 HA 
(8,9). Nevertheless, pigs infected or vaccinated with Euro-
pean SIVs frequently have cross-reactive HI antibodies to 
pandemic (H1N1) 2009 virus and related North American 
SIVs. Two factors predispose for serologic cross-reactivity: 
1) elevated antibody titers to European avian-like subtype 
H1N1 SIVs, as in hyperimmune swine serum and some 
postvaccination serum; and 2) infection with 2 European 
SIV subtypes.
Consecutive experimental infection of pigs with the 
antigenically distinct SIVs of subtypes H1N1 and H1N2 
causes a strong boost of already existing HI antibody ti-
ters to the ﬁ  rst infecting virus, as shown by longitudinal 
investigations (6). These pigs may even develop low levels 
of cross-subtype-reactive HI antibodies to SIV (H3N2). In 
humans and in mice, sequential infections with inﬂ  uenza 
virus variants seemingly lead to a predominant antibody 
response against cross-reactive epitopes on the HA, which 
are shared with the ﬁ  rst infecting virus, whereas the re-
sponse to strain-speciﬁ  c epitopes may be lower (10). Such 
cross-reactive antibodies may cause cross-recognition of 
viruses with a classical H1 HA in our dually infection–
immune pigs, but further studies with monoclonal antibody 
escape mutants are needed to understand cross-reactivity at 
the molecular level. Multiple SIV infections have become 
common in swine-dense regions of Europe since the intro-
duction of the H1N2 subtype in the late 1990s (11).
The HI test will clearly fail to differentiate here be-
tween established SIVs and pandemic (H1N1) 2009 virus. 
This conclusion is further supported by preliminary HI tests 
on sera collected from ﬁ  nishing pigs in Belgium during 
2007. Of 172 serum samples, 35% and 36%, respectively, 
were positive against swine/Iowa/2004 (H1N1) and swine/
Indiana/99 (H1N2); 95% of these positives had antibodies 
to >1 European SIV subtype.
Besides serum antibody to the HA, an infection with 
live inﬂ   uenza virus also stimulates mucosal immunity 
and cellular immune responses to highly conserved viral 
epitopes (12). These responses mean partial protection 
against a subsequent infection with an antigenically un-
related strain may occur in the absence of cross-reactive 
antibodies (13). In contrast, protection offered by inacti-
vated inﬂ  uenza vaccines is almost entirely dependent on 
serum HI antibody titers. Two of the 4 vaccines used in-
duced HI antibody titers against pandemic (H1N1) 2009 
virus that are considered protective. Unexpectedly, avian 
inﬂ  uenza (H1N1) SIV-based vaccine gave higher antibody 
titers than the A/New Jersey/76-based vaccine. The amino 
acid homology between vaccine and test strains is thus a 
less reliable predictor of serologic cross-reactivity than one 
would assume. Our data suggest that preexisting immunity 
to established SIV strains may partially protect pigs in Eu-
rope against pandemic (H1N1) 2009 virus, but the extent 
of such protection needs to be assessed in well-controlled 
challenge experiments. Pandemic (H1N1) 2009 infection 
in pigs in Europe has so far been limited to countries where 
SIVs are absent or circulating at low levels. Whether the 
virus will become established in countries where SIVs are 
widespread remains to be seen.
The divergence between H1 of contemporary seasonal 
inﬂ  uenza (H1N1) viruses of humans and pandemic (H1N1) 
2009 virus is approximately the same as that between SIVs 
in Europe and North America. However, cross-reactive HI 
antibody responses to pandemic (H1N1) 2009 virus have 
been almost exclusively detected in humans born before 
1950 (14). These persons have been exposed to older vari-
ants of seasonal inﬂ  uenza (H1N1) viruses that are more 
closely related to classic swine inﬂ  uenza (H1N1) viruses 
and pandemic (H1N1) 2009 virus. The present epidemio-
logic situation in humans thus differs from that in pigs. 
Two antigenically distinct inﬂ  uenza (H1N1) viruses—sea-
sonal and the 2009 virus—could cocirculate in humans in 
the future. This cocirculation will likely broaden serologic 
responses and protection against inﬂ  uenza but may also 
complicate interpretation of HI test results. 
Acknowledgments
We thank Ilaria Capua, Ruben Donis, and Ralf Dürrwald for 
providing viruses, vaccines, or control serum samples used in this 
study, and Lieve Sys, Melanie Bauwens, Nele Dennequin, and 
Alexander Karasin for excellent technical assistance. 
This study was supported in part by coordination actions in 
the 6th and 7th Framework Research Program of the European 
Commission (ESNIP2, SSPE-CT-2005-022749; FLUTRAIN, 
SSPE-CT-2006-044212).
Dr Kyriakis was a PhD student at the Laboratory of Virol-
ogy, Faculty of Veterinary Medicine, Ghent University, from 
2004 to 2009. He has studied the efﬁ  cacy of inﬂ  uenza vaccines 
for pigs and was involved in the European Surveillance Network 
for Inﬂ  uenza in Pigs 2.  
References
  1.   Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. 
Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) 
inﬂ  uenza viruses circulating in humans. Science. 2009;325:197–201 
10.1126/science.1176225. DOI: 10.1126/science.1176225
  2.   Inﬂ  uenza pandemic (H1N1) 2009, animal (19): Iceland swine, OIE. 
ProMed. 2009 Oct 28. Available from http://www.promedmail.org, 
archive no. 20091028.3737.
  3.   Brookes SM, Irvine RM, Nunez A, Clifford D, Essen S, Brown IH, et 
al. Inﬂ  uenza A (H1N1) infection in pigs. Vet Rec. 2009;164:760–1.
DISPATCHES
98  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 1, January 2010Pandemic (H1N1) 2009 Virus in Pigs
  4.   Lange E, Kalthoff D, Blohm U, Teifke JP, Breithaupt A, Maresch 
C, et al. Pathogenesis and transmission of the novel swine origin 
inﬂ  uenza virus A/H1N1 after experimental infection of pigs. J Gen 
Virol. 2009;90:2119–23.
  5.   Olsen CW, Brown I, Easterday BC, Van Reeth K. Swine inﬂ  uenza. 
In: Straw BE, Zimmerman JJ, D’ Allaire S, Taylor DJ, editors. Dis-
eases of swine, 9th edition. Ames (IA): Iowa State University Press; 
2006. p. 469–82.
    6.    Van Reeth K, Labarque G, Pensaert M. Serological proﬁ  les  af-
ter consecutive experimental infections of pigs with European 
H1N1, H3N2, and H1N2 swine inﬂ  uenza viruses. Viral Immunol. 
2006;19:373–82. DOI: 10.1089/vim.2006.19.373
    7.    Centers for Disease Control and Prevention. Swine Inﬂ  uenza A 
(H1N1) infection in two children—southern California, March–
April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400–2.
  8.   Pensaert M, Ottis K, Vandeputte J, Kaplan MM, Bachmann PA. 
Evidence for the natural transmission of inﬂ  uenza A virus from wild 
ducks to swine and its potential importance for man. Bull World 
Health Organ. 1981;59:75–8.
  9.   Brown IH, Ludwig S, Olsen CW, Hannoun C, Scholtissek C, Hin-
shaw VS, et al. Antigenic and genetic analyses of H1N1 inﬂ  uenza A 
viruses from European pigs. J Gen Virol. 1997;78:553–62.
10.   Kim JH, Skountzou I, Compans R, Jacob J. Original antigenic sin re-
sponses to inﬂ  uenza viruses. J Immunol. 2009;183:3294–301. DOI: 
10.4049/jimmunol.0900398
11.   Van Reeth K, Brown IH, Dürrwald R, Foni E, Labarque G, Lenihan 
P, et al. Seroprevalence of H1N1, H3N2 and H1N2 inﬂ  uenza and 
viruses in pigs in seven European countries in 2002–2003. Inﬂ  u-
enza and Other Respiratory Viruses. 2008;2:99–105. DOI: 10.1111/
j.1750-2659.2008.00043.x
12.   Grebe KM, Yewdell J, Bennink JR. Heterosubtypic immunity to inﬂ  u-
enza A virus: where do we stand? Microbes Infect. 2008;10:1024–9. 
DOI: 10.1016/j.micinf.2008.07.002
13.   Van Reeth K, Gregory V, Hay A, Pensaert M. Protection against a 
European H1N2 swine inﬂ  uenza virus in pigs previously infected 
with H1N1 and/or H3N2 subtypes. Vaccine. 2003;21:1375–81. DOI: 
10.1016/S0264-410X(02)00688-6
14.   Hancock K, Veguilla V, Xiuhua L, Zhong W, Butler EN, Sun H, et 
al. Cross-reactive antibody responses to the 2009 pandemic H1N1 
inﬂ  uenza virus. N Engl J Med. 2009;361:1945–52.
Address for correspondence: Kristien Van Reeth, Laboratory of Virology, 
Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 
B-9820 Merelbeke, Belgium; email: kristien.vanreeth@ugent.be
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 1, January 2010  99 